Merdury Biopharmaceutical

Merdury Biopharmaceutical FCF Yield

The Free Cash Flow Yield of Merdury Biopharmaceutical (6932.TWO) as of Oct 18, 2026 is -1.68 %. In the previous year, Free Cash Flow Yield was -1.33 % — a change of 26.91% (lower).

FCF Yield

-1.68 %

YoY

26.91%

Last updated:

Free Cash Flow Yield of Merdury Biopharmaceutical is 2025 -1.68 % . Free Cash Flow Yield of Merdury Biopharmaceutical was 2024 -1.33 % . It decreases by 26.91% lower compared to the previous year.

The Merdury Biopharmaceutical FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2019
-0.01 TWD
Jan 1, 2020
-0.01 TWD
Jan 1, 2021
-0.36 TWD
Jan 1, 2022
-2.74 TWD
Jan 1, 2023
-1.61 TWD
Jan 1, 2024
-1.33 TWD
Jan 1, 2025
-1.68 TWD
The Merdury Biopharmaceutical FCF Yield history
YEARFCF YieldYoY
-1.68 %+26.91%
-1.33 %-17.78%
-1.61 %-41.04%
-2.74 %+668.63%
-0.36 %+5,565.44%
-0.01 %+10.15%
-0.01 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Merdury Biopharmaceutical Stock analysis

What does Merdury Biopharmaceutical do? Merdury Biopharmaceutical Corp is a pharmaceutical company based in Taipei, Taiwan, operating within the Health Care sector. The company has a small workforce of 13 employees and went public on December 23, 2022, with its ticker listed as 6932.TWO. Merdury Biopharmaceutical Corp focuses on developing drugs that address unmet medical needs, difficult generic drugs, and second-class new drugs. The company utilizes a self-developed drug development platform called StackDose, which enables the creation of tablets with controlled dissolution properties, allowing for either immediate or sustained drug release. This technology supports the development of products such as Sildenafil, Metformin, Tadalafil, Zolpidem, angina treatments, migraine medications, and multi-ingredient antihypertensive drugs. These products are primarily marketed and sold in Taiwan and the United States. The company's website is https://merdury.com, providing further information about its operations and offerings. Merdury Biopharmaceutical Corp operates as a publicly traded entity with a focus on innovative pharmaceutical solutions within the Taiwanese and U.S. markets. Merdury Biopharmaceutical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Merdury Biopharmaceutical stock

Free Cash Flow Yield of Merdury Biopharmaceutical is -1.68 % in 2025.

Free Cash Flow Yield of Merdury Biopharmaceutical changed from -1.33 % to -1.68 %, representing a 26.91% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Merdury Biopharmaceutical since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Merdury Biopharmaceutical with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Merdury Biopharmaceutical

All Key Metrics — Merdury Biopharmaceutical